Atezolizumab Immunotherapy Boosts Survival in Colon Cancer ⁣Treatment

​ Updated June 03, 2025
⁤ ⁣

The‌ ATOMIC trial revealed that⁢ adding ‍atezolizumab immunotherapy too standard⁣ chemotherapy considerably improves survival rates for patients with stage III deficient DNA mismatch repair (dMMR) colon cancer. The study, presented at the⁢ American Society of Clinical Oncology (ASCO) 2025 annual meeting, suggests a ⁣new standard treatment for this patient group.

Standard treatment involves surgery followed ⁢by chemotherapy.However, about 15% of colon cancer ⁣patients ‍have ⁢dMMR, making them​ resistant to⁣ chemotherapy. Dr. Frank A. sinicrope of the Mayo Clinic explained that dMMR tumors accumulate mutations, triggering an ineffective immune response. Immune checkpoint inhibitors like atezolizumab⁤ offer a promising⁢ solution.

The ATOMIC trial included⁢ 712 patients with resected stage III dMMR‍ colon cancer. participants were divided ⁣into ⁣two⁤ groups: one receiving chemotherapy alone and the⁤ other receiving chemotherapy combined with atezolizumab.The three-year disease-free survival⁤ rate was 86.4% in the chemo-immunotherapy group, compared to 76.6% in the chemotherapy-only group.

Sinicrope noted this translates to a 50% reduction in recurrence and death. The‍ benefit was ‌consistent⁣ across various subgroups, including different ages, sexes, and tumor locations. The safety profile was consistent with the known profiles of ‌each drug, with manageable increases in certain adverse events.

Dr.Joel Saltzman from the Cleveland Clinic hailed the results as “dramatic” ‌and practice-changing,emphasizing the relevance to patients seen in clinics every week. He noted that integrating immunotherapy into care has⁢ been a ‌long-awaited possibility.

“These data ​established this combination as a new ⁢standard treatment ⁢for patients with stage III ⁤colon cancer and deficient mismatch repair,” said study author Frank A. Sinicrope,⁢ MD.

Myriam⁢ Chalabi from the Netherlands cancer Institute suggested neoadjuvant immunotherapy might be even more effective, potentially allowing for‍ reduced chemotherapy and surgery. She also​ questioned whether chemotherapy is always necessary⁣ in the adjuvant setting.

Dr. Anwaar Saeed of‍ the University of ​Pittsburgh Medical center echoed this, stating that the ATOMIC trial should be a “launchpad” for further research.A key question is whether​ chemotherapy enhances survival when combined with immunotherapy, or if chemo-free regimens could offer comparable efficacy with‌ fewer toxicities.

What’s next

Future research‌ will focus on optimizing the combination of immunotherapy and chemotherapy, potentially exploring chemo-free regimens to reduce toxicity while maintaining efficacy in treating stage III dMMR colon cancer.